[go: up one dir, main page]

NO932399L - Tiazolylvinylfenylderivater - Google Patents

Tiazolylvinylfenylderivater

Info

Publication number
NO932399L
NO932399L NO932399A NO932399A NO932399L NO 932399 L NO932399 L NO 932399L NO 932399 A NO932399 A NO 932399A NO 932399 A NO932399 A NO 932399A NO 932399 L NO932399 L NO 932399L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
cycloalkyl
alkoxy
hydroxy
Prior art date
Application number
NO932399A
Other languages
English (en)
Other versions
NO932399D0 (no
Inventor
Georg William Holland
John Raymond Vermeulen
William Joseph Zally
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO932399D0 publication Critical patent/NO932399D0/no
Publication of NO932399L publication Critical patent/NO932399L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Forbindelser med formelen: hvor R1 er hydrogen, alkyl, cykloalkyl, karboksyl eller alkoksykarbonyl; R2 er hydrogen, halogen eller alkyl; A er en gruppe med formelen Z og W er uavhengig hydrogen eller alkyl, eller Z og W sammen er alkylen; n er et heltall fra 0-1; m er et heltall fra 0-3; X er -CH2OH eller -R^COR5; Y er halogen, alkoksy, acyloksy, hydroksy, alkyl, nitro, trif luormetyl , hydrogen eller cyano; R3 er hydrogen, alkyl eller cykloalkyl; R4 er en direkte binding eller CH2 ; R5 er hydroksy, alkoksy, NHR6 eller N R8 R6 er hydrogen eller alkyl; og R7 og R8 er uavhengig hydrogen eller alkyl, eller R7 og R8 er sammen alkylen, forutsatt at når m er O og n er O, er en av R1 eller R3 cykloalkyl, og enantiomerer , diastereomerer , racemater og salter med farmasøytisk akseptable baser, antagoniserer LTD4- virkning og er således nyttige ved behandling av bronkial astma, pulmonsr anafylaksi, cystisk fibrose, kronisk bronkitt, bronkieklasi, respirator isk distress- syndrom og pulmonært ødem.
NO932399A 1992-07-02 1993-07-01 Tiazolylvinylfenylderivater NO932399L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/907,987 US5273986A (en) 1992-07-02 1992-07-02 Cycloalkylthiazoles

Publications (2)

Publication Number Publication Date
NO932399D0 NO932399D0 (no) 1993-07-01
NO932399L true NO932399L (no) 1994-01-03

Family

ID=25424972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932399A NO932399L (no) 1992-07-02 1993-07-01 Tiazolylvinylfenylderivater

Country Status (18)

Country Link
US (2) US5273986A (no)
EP (1) EP0577003A1 (no)
JP (1) JPH0680654A (no)
KR (1) KR940005602A (no)
CN (1) CN1087086A (no)
AU (1) AU667107B2 (no)
BR (1) BR9302737A (no)
CA (1) CA2099295A1 (no)
CZ (1) CZ133493A3 (no)
FI (1) FI933037A7 (no)
HU (1) HUT72747A (no)
IL (1) IL106141A0 (no)
MX (1) MX9303958A (no)
NO (1) NO932399L (no)
NZ (1) NZ247988A (no)
PL (1) PL299544A1 (no)
UY (1) UY23609A1 (no)
ZA (1) ZA934603B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
AU3522895A (en) * 1994-09-13 1996-03-29 F. Hoffmann-La Roche Ag A process of making (e)-4-{3-{2-(4-cycloalkyl-2-thiazolyl) ethenyl}phenyl}amino-2 ,2-alkyldiyl-4-oxobutanoic acid anoic acid
JP3061862B2 (ja) * 1994-10-14 2000-07-10 山之内製薬株式会社 アゾール誘導体
WO1996033181A1 (en) * 1995-04-21 1996-10-24 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
SE9804212D0 (sv) * 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
US20050009843A1 (en) * 2001-04-26 2005-01-13 Kiyoshi Nakayama Medicine for inhibiting drug elimination pump
US7056917B2 (en) * 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
RU2392275C2 (ru) * 2004-02-18 2010-06-20 Астразенека Аб Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP4651714B2 (ja) * 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910350A1 (en) * 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
JP2010513445A (ja) * 2006-12-21 2010-04-30 アストラゼネカ アクチボラグ Ｇｌｋアクチベーターとして有用な新規結晶性化合物
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076221A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
IN2012DN02982A (no) 2009-10-02 2015-07-31 Avexxin As
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
WO2019148005A1 (en) * 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
AU2020272937B2 (en) 2019-04-09 2024-09-26 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
WO2020236654A1 (en) 2019-05-17 2020-11-26 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
US20210085717A1 (en) 2019-09-24 2021-03-25 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
JP2024514836A (ja) 2021-04-08 2024-04-03 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂ阻害化合物との組み合わせ療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
JPS63258854A (ja) * 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
DE3723913A1 (de) * 1987-07-18 1989-02-23 Shell Agrar Gmbh & Co Kg Neue phosphoniumsalze, ihre herstellung und verwendung
EP0318085A3 (en) * 1987-11-25 1990-03-14 Merck Frosst Canada Inc. Heterazole dialkanoic acids
US5001140A (en) * 1989-04-17 1991-03-19 Hoffmann-La Roche Inc. Cycloalkylthiazoles
EP0355353B1 (en) * 1988-07-15 1994-03-16 F. Hoffmann-La Roche Ag Cycloalkylthiazole derivatives
JPH02169583A (ja) * 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
AU654140B2 (en) * 1990-07-31 1994-10-27 Lilly Industries Limited N-benzyl indoles, processes for their preparation or pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BR9302737A (pt) 1994-02-08
EP0577003A1 (en) 1994-01-05
CN1087086A (zh) 1994-05-25
CA2099295A1 (en) 1994-01-03
FI933037A7 (fi) 1994-01-03
JPH0680654A (ja) 1994-03-22
UY23609A1 (es) 1993-12-21
NO932399D0 (no) 1993-07-01
NZ247988A (en) 1995-11-27
HUT72747A (en) 1996-05-28
MX9303958A (es) 1994-04-29
HU9301881D0 (en) 1993-09-28
CZ133493A3 (en) 1994-01-19
US5399702A (en) 1995-03-21
ZA934603B (en) 1994-01-05
FI933037A0 (fi) 1993-07-01
US5273986A (en) 1993-12-28
KR940005602A (ko) 1994-03-21
AU667107B2 (en) 1996-03-07
AU4156293A (en) 1994-01-06
PL299544A1 (en) 1994-02-21
IL106141A0 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
NO932399L (no) Tiazolylvinylfenylderivater
FI900531A0 (fi) Tigogenin-cellubiosid foer att skoeta hyperkolesterolemia och arteriosklerosis.
KR100257619B1 (en) Azole compounds, their production and use
NO982913L (no) Kinolin- og kinazolinforbindelser nyttige i terapi
NO20062711L (no) Heterosykliske borsyreforbindelser
ES8707223A1 (es) Un procedimiento para la preparacion de derivados de benzotiazol y benzotiofen.
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
JPS56150014A (en) Antiallergic agent
BG104391A (en) Therapeutically active compounds based on bioisosteric substitution of cathechol in pde4 inhibitors with indazole
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
JP2004516293A5 (no)
IE893294L (en) Piperidinyl benzimidazoles
CA2164303A1 (en) Aromatic Acetylcholinesterase Inhibitors
CA2207097A1 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
ATE31921T1 (de) Amidine, verfahren zu ihrer herstellung und deren anwendung in der therapie.
NO985040L (no) FremgangsmÕte for inhibering av vaskulµrcelleadhesjonsmolekyl-1 og behandling av kroniske, inflammatoriske sykdommer med 2,6-dialkyl-4-silylfenoler
NO900697L (no) Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
NZ333257A (en) Substituted cyclohexyl-phenyl-glycolates as spasmolytic agents
DE69525633D1 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
NO943567L (no) Bruede bis-arylcarbinolderivater, preparater og anvendelsesmetoder
CA2246584A1 (en) Method of treating tourette's syndrome
WO1986007059A3 (en) Oxodiazine compounds
RU93048130A (ru) Производные тиазолилвинилфенила
NZ332029A (en) Sulfonamide substituted chromans, process for their preparation, their use as a medicament and pharmaceutical preparations comprising them
ATE46156T1 (de) 1,3-benzoxathiol-derivate, deren verwendung und deren herstellung.